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SNPsThe Gilbert syndrome is a benign form of unconjugated hyperbilirubinemia, mainly associated with alter-
ations in UGT1A1 gene. This work investigated the effect of UGT1A1 variants on total bilirubin levels in Gilbert
patients (n=45) and healthy controls (n=161). Total bilirubin levels were determined using a colorimetric
method; molecular analysis of exons 1–5 and two UGT1A1 promoter regions were performed by direct se-
quencing and automatic analysis of fragments. Five in silico methods predicted the effect of new identiﬁed
variants.
A signiﬁcant different allelic distribution, in Gilbert patients and in controls, was found for two promoter poly-
morphisms. Amongpatients, 82.2%were homozygous and 17.8% heterozygous for the c.−41_−40dupTA allele;
in control group, 9.9%were homozygous and 43.5% heterozygous for this promoter variant, while 46.6% (n=75)
presented the [A(TA)6TAA]. For the T>G transition at c.−3279 promoter region, in patients, 86.7% were homo-
zygous and 13.3% heterozygous; in control group, 33.5% were homozygous for the wild type allele, 44.1% were
heterozygous and 22.4% homozygous for the mutated allele. The two polymorphisms were in Hardy–Weinberg
equilibrium in both groups. Sequencing of UGT1A1 coding region identiﬁed nine novel variants, ﬁve in patients
and four in controls. In silico analysis of these amino acids replacements predicted four of them as benign and
three as damaging.
In conclusion, we demonstrated that total bilirubin levels are mainly determined by the TA duplication in the
TATA-box promoter and by the c.−3279T>G variant. Alterations in the UGT1A1 coding region seem to be as-
sociated with increased bilirubin levels, and, therefore, with Gilbert syndrome.
© 2012 Elsevier Inc. All rights reserved.Introduction
Gilbert syndrome (GS, OMIM 606785) is an autosomal recessive
condition characterized by unconjugated hyperbilirubinemia in the
absence of hemolysis or underlying liver disease [1], due to the re-
duced activity of uridine diphosphate-glucuronosyltransferase
(UGT1A1). This enzyme is mainly expressed in the liver and has an
important role in the glucuronidation of bilirubin, 17β-estradiol [2],
some therapeutic drugs [3] and mutagenic xenobiotics [4]. Absence
or severe reductions of UGT1A1 activity are associated with Crigler-
Najjar syndrome type I [5] and type II [6], respectively. Crigler Najjar
syndrome is an autosomal recessive disease; so a subject must beBiológicas, Laboratório de Bio-
orto, Rua Anibal Cunha, 164,
cha).
rights reserved.carrying at least two mutations in trans to manifest the disease.
Only one mutation should not affect the TBL levels. However, if such
nucleotide substitution is in trans with an allele carrying the
A(TA)7TAA allele (c.−41_−40dupTA) it is possible that the bilirubin
levels could be compatible with the GS or with Crigler Najjar type II
syndrome [7].
The UGT1A1 gene locus has beenmapped to chromosome 2q37 [8],
has nine potential functional exon 1 sequences at the 5′ end of the
gene that can be joint with the constant exons 2–5 at the 3′ end [3].
One of the most common genetic variants is a repeat polymorphism
in the TATA box region of the UGT1A1 promoter. This allele variant
consists of seven thymine adenine (TA) repeats, in the A(TA)nTAA
motif, while the common allele is characterized by the presence of
six TA repeats [A(TA)6TAA]. Homozygous individuals carrying the
A(TA)7TAA allele (c.−41_−40dupTA) have higher levels of unconju-
gated bilirubin, caused by a reduction of 30% in UGT1A1 transcription
[9]. The estimated frequency of this allele is 0.35 in Caucasians,
Table 1
Primers used for the ampliﬁcation of the UGT1A1 exons and promoter's regions.
UGT1A1
region
Primer name Sequence (5′→3′) Reference
Promotor UGT1A1-TAF 5′-TAACTTGGTGTATCGATTGGTTTTTG-3′ 21
UGT1A1-TAR 5′-ACAGCCATGGCGCCTTTGCT-3′
UGT1A1-Reg 5′-CTA GCC ATT CTG GAT CCC TTG-3′ 16
UGT1A1-Reg 5′-TTTTGAGATCTGAGTTCTCTTCACCTC-3′
Exon 1 UGT1A1-1aF 5′-TATAAGTAGGAGAGGGCGAACC-3′ This study
UGT1A1-1aR 5′-TCAAATTCCAGGCTGCATG-3′
UGT1A1-1bF 5′-GGCCTCCCTGGCAGAAAG-3′
UGT1A1-1bR 5′-ATGCCAAAGACAGACTCAAACC-3′
Exon 2 UGT1A1-2 F 5′-TCTATCTCAAACACGCATGCC-3′ 20
UGT1A1-2R 5′-GGCAGGGAAAAGCCAAATCTA-3′
Exon 3 UGT1A1-3 F 5′-TTGCCAGTCCTCAGAAGCCTT-3′ 20
UGT1A1-3R 5′-ATGCCCTTGCAGAAATTTGC-3′
Exon 4 UGT1A1-4 F 5′TGCAAGGGCATGTGAGTAACA-3′ 20
UGT1A1-4R 5-′AAGCCAAGATTGCACCACTG-3′
Exon 5 UGT1A1-5 F 5′-GAGGATTGTTCATACCACAGG-3′ 20
UGT1A1-5R 5′-GCACTCTGGGGCTGATTAAT-3′
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but the frequency is highly variable in different ethnicities [10,11].
Homozygosity for the TA duplication was considered as the main
cause of GS in Caucasian population [9,10], and justiﬁes some of the
inter-individual variations in bilirubin levels, even in the normal pop-
ulation [12]. However, individuals with normal bilirubin levels and
without clinical diagnosis of GS can also show this polymorphism in
homozygosity [3,9]. Thus, this polymorphism appears to be necessary
for GS, but it is not sufﬁcient for the complete manifestation of the
disease [12]. Another promoter polymorphism, a T>G transition at
position −3279, at the phenobarbital responsive enhancer module
(gtPBREM), has also been associated with GS [13,14]. In Caucasian
and Japanese patients this polymorphism was described and referred
to be in linkage disequilibrium with the TA duplication (c.−41_
−40dupTA) [13–16]. In the last years more than 100 single nucleo-
tide polymorphisms (SNPs) have also been described within the
UGT1A1 gene [3].
The aim of the present work was the analysis of the impact of both
promoter and/or coding region of UGT1A1 variants on bilirubin levels,
in GS patients and in healthy controls. Additionally, bioinformatics
tools were used to study the new identiﬁed variants in order to eval-
uate their clinical impact.
Patients and methods
Subjects
This study included 45 GS Caucasian patients (36 males and 9 fe-
males, with a mean age of 45±13.2 years) of the gastroenterology
department of Vila Nova de Gaia/Espinho Hospital Center, EPE, with
clinical diagnosis of GS, based on standard criteria [17,18]. Hyperbilir-
ubinemia was deﬁned as a concentration of total bilirubin above
17.1 μmol/L. Data from GS patients were obtained from medical re-
cords. Total bilirubin levels (TBL) correspond to the median of three
bilirubin measurements, and every GS patients presented normal
physical examination, liver function tests and blood cell counts.
Healthy control volunteers (n=161; 45 males and 116 females;
mean age of 21.7±5.6 years) were included in this work. Healthy
controls were selected based on normal liver and/or hematological
values, no history of inﬂammatory or malignancy diseases, and of reg-
ular medication. Control participants were also excluded when conju-
gated bilirubin was more than 20% of total bilirubin. GS patients and
healthy controls, gave their informed consent to participate in this
study.
Samples and measurements
Blood samples were collected in the morning after 8 h of fasting,
using EDTA as anticoagulant, in order to obtain plasma and buffy
coat for DNA extraction. TBL concentration was determined by using
a colorimetric method (diazotized sulfanilic acid reaction; Roche Di-
agnostics Co, Indianapolis). Genomic DNA was extracted from blood
samples using standard salting out method [19].
Genotyping
All patients and controls were screened for the presence of the TA
insertion in the TATA box region of UGT1A1 gene by PCR ampliﬁca-
tion, with the introduction of a ﬂuorochrome label (NED™) in the re-
verse primer, as previously described [20,21]. Direct sequencing of
the ﬁve exons, and the gtPBREM (c.−3576 to c.−3209) region of
UGT1A1 gene was done in independent sequencing reactions, using
the respective forward and reverse primers (Table 1), and by the
Dye Terminator Cycle Sequencing Kit (Perkin Elmer, Boston, USA).
The protocol of cycling was performed on a DNA thermal cycler Gen-
eAmp PCR System 9700 (Applied Biosystems, Foster City, USA). Theresulting products were subsequently analyzed by automated capil-
lary electrophoresis (ABI Prism 3130xl® Genetic Analyser, Applied
Biosystems, Foster City, USA), using the GeneMapper v4.0 along
with the molecular weight marker GeneScan ROX™ 500 Size Stan-
dard (Applied Biosystems, Foster City, USA).
Bioinformatics tools
For primers design, we used the Primer Express® software (Ap-
plied Bioystems, Foster City, USA). The analysis of sequence results
were performed on SeqScape™ version 2.5, and Finch TV version
1.3 (http://www.geospiza.com/ﬁnchtv). Sequence analyses were car-
ried out using the reference sequence (rs) from GenBank (accession
number NM_000463.2) and amino acid reference sequence from
GenePret (accession number P22309). The annotation of the muta-
tions was done according to the recommendation of the Human Ge-
nome Variation Society. The homozygous and heterozygous
individuals for the TA polymorphism c.−41_−40dupTA were cate-
gorized as [TA]7/[TA]7 and [TA]7/[TA]6, respectively, and those that
were homozygous for the wild type allele were referred as [TA]6/
[TA]6. The homozygous and heterozygous for the polymorphism
c.3279T>Gwere categorized as G/G and T/G, respectively, and the ho-
mozygous for the wild type allele as T/T.
The potential pathogenicity of the new variants and the corre-
spondent altered sequences were analyzed by Alamut software v.1.5
(Interactive Biosoftware, Rouen, France) that performs an in silico
analysis using methods based on sequence homology, protein struc-
ture information and amino acid physicochemical properties. The
methods used in this analysis were: Polymorphism Phenotyping
(PolyPhen-2) [22]; Sorting Intolerant from Tolerant (SIFT) [23];
Align Grantham Variance-Grantham Difference (A-GVGD) [24]; Gran-
tham score [25]; BLOSUM 62 matrix score (BLOSUM62) [26].
Statistical analysis
For statistical analysis, we used the Statistical Package for Social
Sciences-SPSS version 18.0 for Windows (SPSS Inc., Chicago, USA).
χ2 or Fisher's exact tests were used to compare genotype allele fre-
quencies between groups. Bilirubin, the dependent variable, was
Log transformed to obtain a normalized data. Independent Student
t test was used to compare total bilirubin values between male and
female subjects. Multiple comparisons between groups were per-
formed by one-way ANOVA supplemented with Tukey's HSD post
hoc test. The pairwise (Lewontin's) D′ and correlation coefﬁcient
(r2) values of linkage disequilibrium for the variation of the
c.−3279T>G with the polymorphism c.−41_−40dupTA was
Table 2
Genotypes frequencies and TBL values of UGT1A1 c.−41_−40dupTA and c.−3279T>G polymorphisms in GS patients and in controls.
Polymorphism GS patients Controls
% (n) TBL (μmol/L) % (n) TBL (μmol/L) p*
c.−41_−40dupTA
[TA]6/[TA]6 0%(0) – 46.6% (75) 7.5±3.2 b0.0001
[TA]6/[TA]7 17.8%(8) 27.7±12.5 43.5% (70) 9.6±4.6a
[TA]7/[TA]7 82.2%(37) 37.9±13.3 9.9% (16) 19.5±9.9b,c
c.3279T>G
TT 0%(0) – 33.5% (54) 7.7±3.1 b0.0001
TG 13.3%(6) 28.3±5.8 44.1% (71) 8.9±4.5
GG 86.7%(39) 36.8±13.3b 22.4% (36) 13.8±8.8b,c
TBL: total bilirubin levels that are presented as mean±standard deviation (SD); *p-value for differences in allelic distribution between controls and GS patients. p-value b0.05 for
TBL between different genotypes: awild type vs. heterozygous; bhomozygous for the mutated alleles vs. heterozygous; chomozygous for the mutated alleles vs. wild type.
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software/cubex/ [27]. Signiﬁcance was accepted at pb0.05.
Results
In this work, we ﬁrst analyzed the impact of promoter's polymor-
phisms in TBL, considering the nine possible diplotypes. After that, we
also evaluated the inﬂuence of coding region of UGT1A1 variants in
TBL. The impact of new variants in the UGT1A1 gene was estimated
by in silico methods.
Promoter UGT1A1 variants
Results from genotyping revealed the presence of two promoter
polymorphisms, c.−41_−40dupTA and c.−3279T>G, in both
groups (GS patients and controls) with signiﬁcant different allelic
distribution (Table 2). Among GS patients, 82.2% (n=37) were ho-
mozygous and 17.8% (n=8) were heterozygous for the c.−41_
−40dupTA allele. In the control group, we found that 9.9%
(n=16) were homozygous and 43.5% (n=70) were heterozygous
for this promoter variant, and 46.6% (n=75) presented the six TA
repeats [A(TA)6TAA]. For the T>G transition located at c.−3279
nucleotide, we found that 86.7% (n=39) were homozygous and
13.3% (n=6) were heterozygous for the c.−3279T>G variant in
GS patients. In the control group, we found that 33.5% (n=54)
were homozygous for the wild type allele, 44.1% (n=71) were het-
erozygous and 22.4% (n=36) were homozygous for the
c.−3279T>G variant. The two polymorphisms were in Hardy–
Weinberg equilibrium in control group. Results of linkage disequi-
librium, for the association of the two promoter polymorphisms,
showed that D′ and r′ values were 1.0 and 0.57, respectively, con-
ﬁrming existence of the close linkage the disequilibrium between
them.
From the nine possible diplotype combinations, four were found
in GS patients and six in controls. The frequencies of combined diplo-
types in GS patients and controls are shown in Table 3.Table 3
GS patients and controls diplotype frequencies and its relationship with TBL.
Diplotype
(c.−41_−40dupTA/c.−3279T>G)
GS patients
% (n) TBL (μmol/
[TA]6/[TA]6 -TT 0% (0) –
[TA]6/[TA]6 -TG 0% (0) –
[TA]6/[TA]7-TG 8.9% (4) 27.8±7.4
[TA]7/[TA]7-TG 4.4% (2) 29.1±0.5
[TA]6/[TA]6-GG 0% (0) –
[TA]6/[TA]7-GG 8.9% (4) 34.8±7.6
[TA]7/[TA]7-GG 77.8% (35) 37.9±13.3
TBL: total bilirubin levels that are presented as mean±standard deviation (SD); ap-value fo
[TA]7/[TA]7-G/G TBL and other diplotypes.Coding region of UGT1A1 variants
Sequencing analysis of the coding regions of the UGT1A1 gene
allowed the identiﬁcation of nine additional SNPs, all of them in a het-
erozygous state. From these, ﬁve were identiﬁed in GS patients and
four in controls (Table 4). Seven of these variants were new
c.538G>C, c.643A>G, c.814A>G, c.1156G>A; c.1211T>C; c.1423C>T;
c.1475T>C (Fig. 1), and two were already described in literature,
c.674T>G [6] and c.923G>A [28]. Moreover, three of these new variants
were detected in GS patients (c.538G>C; c.1211T>C; c.1423C>T) and
four in controls (c.643A>G; c.814A>G; c.1156G>A; c.1475T>C).
Amino acid conservation analysis was performed by using non-
redundant alignment of homologous sequences, and the results
from amino acid changes as well as the association with
c.−41_40dupTA and c.−3279T>G, are described in Table 4. The
new sequence variants detected were located at the intraluminal
part of the C-terminal half of the UGT1A1 protein that includes the
domain that binds the UDP glucuronic acid (UDPGA) donor substrate,
in both GS patients (p.E180Q; p.V225G) and controls (p.I215V;
p.M272V); at the donor-binding region (residues: 292–409), in GS
patients (p.G308E; p.M404T; p.R475C) and in controls (p.V386I);
and one at reticulum endoplasmic-anchoring transmembrane do-
main (residues: 491–507), in a healthy control (p.I492T). Only one
exchanged amino acid, the glycine 308, was highly conserved
among homologous sequences. The majority of others residues were
moderately conserved and three were weakly conserved (Table 5).
Data regarding the new variants showed that four of them were an-
ticipated to be benign (p.E180Q; p.I215V; p.M272V; p.V386I), while
three were expected to have an effect on protein function
(p.M404T; p.475 C; p.I492T). Functional prediction of the conse-
quence of these amino acid replacements in the UGT1A1 protein, per-
formed by the different in silico methods, was in agreement for the
variants p.M404T, p.R475C, and p.I215V (Table 5).
Additionally, we also detected four previously described polymorphic
variants in GS patients and controls: c.864+89C>T (rs.17868341);
c.997-86C>T (rs.34082659); c.997-82T>C (rs.12471326); and c.997-
37T>C (rs.2471326).Controls
L) % (n) TBL (μmol/L) pa
33.5% (54) 7.7±3.1 b0.0001
11.2% (18) 6.9±3.4
32.9% (53) 9.6±4.9
0% (0) –
1.9% (3) 8.4±3.8
10.6% (17) 9.5±4.3
9.9% (16) 19.5±9.9b
r difference in total bilirubin levels between the several diplotypes; bp-value b0.05 for
Table 4
UGT1A1 gene variants and TBL in GS patients and controls.
TBL (μmol/L) cDNA variation Effect on protein Polymorphism c.−41_−40dupTA Polymorphism c.−3279T>G References
Patients
1/GS 29.4 c.538G>C p.E180Q [TA]7/[TA]7 T/G This study
2/GS 27.7 c.674T>G p.V225G [TA]6/[TA]7 T/G [6]
3/GS 50.1 c.674T>G p.V225G [TA]7/[TA]7 G/G [6]
4/GS 54.2 c.923G>A p.G308E [TA]6/[TA]7 G/G [28]
5/GS 36.6 c.1211T>C p.M404T [TA]7/[TA]7 G/G This study
6/GS 51.3 c.1423C>T p.R475C [TA]6/[TA]7 G/G This study
Controls
1/C 5.1 c.643A>G p.I215V [TA]6/[TA]7 T/G This study
2/C 10.1 c.814A>G p.M272V [TA]7/[TA]7 G/G This study
3/C 4.3 c.1156G>A p.V386I [TA]6/[TA]6 T/T This study
4/C 5.8 c.1475T>C p.I492T [TA]6/[TA]7 T/G This study
The annotation of the mutations was done according to the recommendation of the Human Genome Variation Society. The ﬁrst A in the UGT1A1 start codon was considered as
position 1. TBL: total bilirubin levels.
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The median of TBL (mean±SD) presented for GS patients
was 36.0±12.7 μmol/L (33.4±15.8 μmol/L for females and 35.6±
13.1 μmol/L for males, p=0.667), and 9.5±5.8 μmol/L (9.2±
6.1 μmol/L for females, and 9.9±4.5 μmol/L for males, p=0.529) for
controls. No signiﬁcant differences were found in TBL, according to
gender, between GS patients and controls.
In GS patients, the presence of homozygousity for the two pro-
moter polymorphisms, c.−41_−40dupTA and c.−3279T>G, wereFig. 1. Partial sequences of exons 1, 2, 4 and 5. Arrows indicate the position of nucleotide su
p.M272V; (D) — p.V386I; E — p.M404T; (F) — p.R475C; (G) — pI492T.associated with signiﬁcant increased TBL. Analyzing TBL between
the different dyplotypes of GS patients, we didn't ﬁnd statistically
signiﬁcant differences between the four combinations (Table 3). In-
crements in TBL were observed in GS patients with a diplotype het-
erozygous for c.−41_−40dupTA and homozygous for c.3279T>G,
but without statistical signiﬁcance (34.8±7.6 vs. 27.8±7.43 mol/L;
p=0.254). The same was observed for diplotype [TA]7/[TA]7-T/G,
as compared to diplotype [TA]7/[TA]7-G/G (29.1±0.5 vs. 37.9±
13.3 μmol/L; p=0.275). Only one GS patient (2/GS, Table 2) was
identiﬁed in heterozygosity for both promoters polymorphism; thebstitution at the seven novel identiﬁed variants. (A) — p.E180Q; (B) — p.I215V; (C) —
Table 5
Functional predictions of UGT1A1 variants by three algorithms based in homology (Polyphen-2; SIFT; A-GVGD) and two based in amino acid physiochemical properties (Grantham
Distance and BLOSUM62 matrix score).
Amino acid
conservation
In silico evaluation (prediction and scores)
Variant Exon Domain Polyphen-2a SIFTb A-GVGDc Grantham Distanced BLOSUM62e
GS patients
p.E180Q 1 Aglycone-recognition Weakly conserved Possibly damaging Tolerated (0.25) C0 Tolerated (29) Tolerated (2)
p.V225Gf 1 Aglycone-recognition Weakly conserved Benign Deleterious (0.03) C0 Deleterious (109) Deleterious (−3)
p.G308E f 2 Donor-binding Highly conserved Probably damaging Deleterious (0.0) C0 Deleterious (98) Deleterious (−2)
p.M404T 4 Donor-binding Moderately conserved Probably damaging Deleterious (0.03) C0 Deleterious (81) Deleterious (−1)
p.R475C 5 Donor-binding Moderately conserved Probably Damaging Deleterious (0.02) C0 Deleterious (180) Deleterious (−3)
Controls
p.I215V 1 Aglycone-recognition Weakly conserved Benign Tolerated (1.0) C0 Tolerated (29) Tolerated (3)
p.M272V 1 Aglycone-recognition Moderately conserved Probably damaging Tolerated (0.27) C0 Tolerated (21) Tolerated (1)
p.V386I 4 Donor-binding Moderately conserved Probably damaging Tolerated (0.47) C0 Tolerated (29) Tolerated (3)
p.I492T 5 Transmembrane segment Moderately conserved Probably damaging Tolerated (0.24) C0 Deleterious (89) Deleterious (−1)
a Qualitative classiﬁcation given by Polyphen: probably damaging, possibly damaging and benign.
b Sort Intolerant from Tolerant, a tolerance index ≤0.05 is considered to be deleterious.
c Align GVGD classiﬁers range from C65 (most likely deleterious) to C0 (most likely neutral).
d Grantham Distance classiﬁed amino acid substitutions as either tolerated (score b60) or deleterious (score ≥60).
e BLOSUM62 (Blok Substitution Matrix), scores≥0 were considered tolerated.
f Variants already described in literature.
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two promoter regions, beyond the variants identiﬁed in the coding
regions, but all of them presented high values of bilirubin
(Table 4). The polymorphic variants already described in literature
(c.864+89C>T, c.997-86C>T, c.997-82T>C, and c.997-37T>C)
seem to have no inﬂuence in TBL.
In healthy subjects, signiﬁcant differences in TBL were obtained
comparing individuals homozygous for the wild type alleles with
those heterozygous for the c.−41_−40dupTA polymorphism
(pb0.03). However, when we compared individuals homozygous for
the wild type alleles with those heterozygous for the c.−3279T>G
transition, no signiﬁcant differences were found (p=0.459). The
presence of homozygousity for the two promoter polymorphisms,
c.−41_−40dupTA and c.−3279T>G, were associated with signiﬁ-
cantly increased TBL (Table 3). Nevertheless, from sixteen homozy-
gous for the TA duplication, which were also homozygous for the
c.−3279G allele, only six of them (37%) had normal bilirubin concen-
trations (TBLb17.1 μmol/L).
Discussion
Several studies aimed to clarify the inﬂuence of genetic and
non-genetic factors in bilirubin levels. GS is one of the most prevalent
congenital metabolic disorders in the population, which is mainly as-
sociated with defects in UGT1A1 gene [7,9,12,29]. The twomajor poly-
morphisms associated to increased TBL in GS Caucasian patients
are the c.−41_−40dupTA and the c.−3279T>G polymorphisms,
[9–16,30–33]. In this work, we analyzed the inﬂuence of UGT1A1
gene variants on TBL in healthy subjects and in GS patients. This anal-
ysis was performed independently in the two groups, due to the dif-
ferences in age between them.
According to our results and in agreement with literature
[9,10,13], homozygosity for the c.−41_−40dupTA allele is strongly
associated with higher bilirubin levels. The c.−3279T>G poly-
morphism has been described as another important factor for the
development of hyperbilirubinemia [14–16,30–33]. Experimental
observations suggested that this variant, located at the
phenobarbital-responsive enhancer module, contributes to a decrease
of 62% of the transcriptional activity of UGT1A1 gene [13]. Moreover, a
recent in vitro study suggests a possible combined effect of these two
polymorphisms (c.−41_−40dupTA and c.−3279T>G) on transcrip-
tional activity of UGT1A1 gene, which further contributes for GS phe-
notype [34]. Our work showed that, both healthy individuals and GS
patients who have double homozygosity for these two variants pre-
sent increased TBL. In fact, we found a linkage disequilibrium betweenthese two polymorphisms [Lewontin's (D′=1) and correlation coefﬁ-
cient (r2=0.57)], which is in accordance with previous studies done
by Borucki et al. (D=1; r2=0.67) [30], Innocenti et al. (D=1;
r2=0.65) [31], Jirsa et al. (D=1; r2=0.66) [32], and Ferraris et al.
(D=0.89; r2=0.57) [33]. This close linkage disequilibriummakes dif-
ﬁcult the evaluation of the independent contribution of each polymor-
phism in TBL.
In this study, the impact of the two polymorphisms in TBL, in
healthy individuals and GS patients, was ﬁrst analyzed independent-
ly. The differences in TBL were more signiﬁcant between the three ge-
notypes of the c.−41_−40dupTA polymorphism than between the
three genotypes of c.−3279T>G polymorphism (Table 2).
No signiﬁcant differences were observed between homozygous
and heterozygous for the mutated alleles, in GS patients. In four of
our GS patients, heterozygous for one or both of the two promoter
polymorphisms, we detected another variant at the exonic region
(Table 4).
The low penetrance of these two variants was evident in our con-
trol group as we found sixteen homozygous for both variants and six
of them had normal bilirubin levels. In GS patients and controls, we
didn't ﬁnd statistically signiﬁcant differences in TBL between most
of diplotypes, a result that may be a consequence of the small sample
size of most of the diplotypes observed. However, we found that the
diplotype [TA]7/[TA]7-G/G is associated with the highest TBL.
Variants in the promoter and coding regions of UGT1A1 may co-
exist in GS patients and healthy controls [6,7,9,28,35–38]. By direct
sequencing of these regions, we identiﬁed for the ﬁrst time seven var-
iants, three in GS patients (c.538G>C; c.1211T>C; c.1423C>T) and
four in controls (c.643A>G; c.814A>G; c.1156G>A; c.1475T>C).
The sequence variant c.1211T>C (p.M404T) is positioned at the
donor-binding site of the UGT1A1 protein. Close to this position,
two other altered residues, the c.1198A>G (N400D) [36] and
c.1207 C>T (R403C) transitions [37], were described and associated
with Crigler-Najjar syndrome type II. The variant c.1423 C>T
(p.R475C), also located at donor-binding site, might alter the tertiary
structure of the protein. The variant c.923 G>A (p.G308E), initially
described by Erps and co-workers [28] is located in a highly con-
served residue, and results in lack of enzyme activity. This substitu-
tion was described as the second most frequent variant of UGT1A1
gene associated to GS in the Portuguese population [20].
In silico analysis, performed by four different methods, predicted
in agreement that three of the amino acid changes (p.M404T,
p.R475C and p.G308E) had a deleterious effect on UGT1A1 activity.
Only the A-GVGD score gave a different prediction, classifying these
variants and all the others as most likely neutral, even for the
171C. Rodrigues et al. / Blood Cells, Molecules, and Diseases 48 (2012) 166–172p.G308E transition, described as an inactivating alteration. Another
variant with potentially negative impact in UGT1A1 activity was
p.V225G, in exon 1, according to the consensual results of three in
silico methods. This variant was described in association with
Crigler-Najjar syndrome type II [6]. These divergences could be due
to the fact that A-GVGD has better speciﬁcity than sensitivity (low
risk of false positive pathogenic prediction), while SIFT and PolyPhen
provide better sensitivity (low risk of false negative neutral predic-
tion) [39]. We also identiﬁed p.V225G variant in two GS patients.
The threonine instead of an isoleucine, at residue 492 (exon 5), was
detected in a control individual that was also heterozygous [TA]6/
[TA]7-T/G for the promoter polymorphisms. Three algorithms predict
a deleterious outcome of this substitution; however, the individual
presented normal levels of total bilirubin.
Four variants were predicted to be benign, one in a GS patient
(p.E180Q) and three in controls (p.I215V, p.V386I, p.I492T). The
p.E180Q transition could be a benign variant, according to four algo-
rithms, with the exception of Polyphen-2, which classiﬁed this variant
as possibly damaging, as it can affect the protein function or structure.
Regarding the three variants found in the control sample, one was pre-
dicted to be benign by all algorithms (p.I215V) and the other two
(p.V386I, p.I492T) were classiﬁed as benign by four algorithms. These
variants were not associated to hyperbilirubinemia. The potential effect
of 63 known UGTs non-synonymous (ns) SNPs on protein function was
previously evaluated [40] and data obtained showed that SIFT and Poly-
phen had a correct prediction rate of 51.1% and 66.7%, respectively.
However, we noticed, in the present study, that SIFTS and Polyphen
were in divergence, comparing to the other methods, in ﬁve of the
nine identiﬁed variants. This suggests the needs for additional in silico
methods with a strong predicton of nsSNP pathogenicity. Nevertheless,
together with the studies of in silico analysis, it is important to know the
allelic phase of the nucleotide substitutionwith two promoter polymor-
phisms of the UGT1A1 gene.
In the ﬁve patients carrying predicted deleterious variants identiﬁed
in the coding region, the mean TBL concentrations was not signiﬁcantly
higher, when compared to the majority of the individuals with the
[TA]7/[TA]7-G/G diplotype (42.1±9.3 vs. 35.9±12.4 μmol/L; p=0.230),
except three patients (3/SG, 4/SG and 6/SG)who had some of the highest
TBL values observed. From the eight patients heterozygous for the [TA]7
(four heterozygous for G/T and four homozygous for G/G), three of
them had another variant, potentially deleterious, in the coding region.
Regarding the alteration p.V225G, patient 2/SG was a compound hetero-
zygous for the TA duplication and c.−3279T>Gpolymorphism,while pa-
tient 3/GS was homozygous for both mutated alleles [TA]7/[TA]7-G/G. In
these two cases,we can observe that the presence of a homozygous diplo-
type increases bilirubin median values (patient 2/SG had a TBL value of
27.7 μmol/L and patient 3/SG had 50.1 μmol/L). The higher TBL observed
in 3/GS patient seems to be conditioned by the presence of the [TA]7/
[TA]7-G/G diplotype.
In conclusion, our data showed that TBL are mainly determined by
the presence of the TA duplication in the repetitive TATA-box se-
quence of the gene promoter, and that the c.−3279T>G variant is
an additional factor for the development of hyperbilirubinemia.
Moreover, our results also revealed that the presence of variants in
the UGT1A1 coding region seems to be associated with increased bil-
irubin levels, and therefore, linked with GS. Thus, the genetic diagno-
sis for GS should include the determination of both promoter
polymorphisms, and the genetic analysis of the entire coding region
namely when the homozygosity for both polymorphisms is not ob-
served. Additionally, we described for the ﬁrst time seven new vari-
ants in the coding region of the gene, expanding the spectrum of
the known UGT1A1 variants.
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